1.
Timothy P. Hughes, Andreas Hochhaus, Hagop M. Kantarjian, Francisco Cervantes, Fran├žois Guilhot, Dietger Niederwieser, Philipp D. le Coutre, Gianantonio Rosti, Gert Ossenkoppele, Clarisse Lobo, Hirohiko Shibayama, Xiaolin Fan, Hans D. Menssen, Charisse Kemp, Richard A. Larson, Giuseppe Saglio. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. haematol [Internet]. 2014Jul.1 [cited 2022Sep.28];99(7):1204-11. Available from: https://haematologica.org/article/view/7085